Abstract:Most therapeutics are small molecules that function by interacting with specific protein targets. Consequently, delineating the protein targets, including the specific binding sites, for chemical probes and clinical candidates is essential to ensure potent on-target activity and to minimize engagement of unfavorable off-targets. The pairing of mass spectrometry-based chemoproteomics with photoaffinity labeling (PAL) has emerged as a favored approach to generate proteome-wide target engagement maps for reversible compounds. However, a key limitation of most PAL-based proteomic platforms is the absence of strategies that report precise binding sites and enable direct head-to-head comparisons of relative target engagement at these sites by different lead compounds. This gap stems from a confluence of factors including the complex fragmentation patterns for crosslinked peptides, poor recovery of peptides crosslinked with large hydrophobic molecules, and modification masses that differ between molecules of interest (MOI). To address these challenges, here we establish the Silyl Ether Enables Chemoproteomic Interaction and Target Engagement (SEE-CITE) approach. SEE-CITE incorporates an unprecedented fully functionalized chemically cleavable crosslinking handle that enables precise site-of-labeling identification and head-to-head comparisons of relative binding site engagement by chemically diverse compounds. To ensure high confidence localization of labeled residues, we also enabled enhanced mapping of photocrosslinked sites by extending the MSFragger algorithm of the FragPipe computational platform to report localization scores customized for PAL and SEE-CITE data. By benchmarking SEE-CITE using scout fragments and analogues of the FDA-approved kinase inhibitors dasatinib and asciminib, we identify known and novel binding sites, including for high impact targets, such as BCR-ABL1, STING, and COX5A.

Chemoproteomic Profiling of a Pharmacophore-Focused Chemical Library.

A Proteomic Landscape of Pharmacologic Perturbations for Functional Relevance

An immuno-chemo-proteomics method for drug target deconvolution

Chemical tools to expand the ligandable proteome: diversity-oriented synthesis-based photoreactive stereoprobes

Chemoproteomics, A Broad Avenue to Target Deconvolution

Chemical proteomic mapping of reversible small molecule binding sites in native systems

Enhanced mapping of small-molecule binding sites in cells

Ligand and Target Discovery by Fragment-Based Screening in Human Cells

[Chemical Proteomics and Discovery of Drug Targets].

Large-scale chemoproteomics expedites ligand discovery and predicts ligand behavior in cells

Therapeutic Target Identification and Drug Discovery Driven by Chemical Proteomics

Exploiting Chemical Probes for Identifying Drug Target Proteins

Enhancing the Small-Scale Screenable Biological Space beyond Known Chemogenomics Libraries with Gray Chemical Matter─Compounds with Novel Mechanisms from High-Throughput Screening Profiles

Chemical proteomics accelerates the target discovery of natural products

Chemical Proteomics-based Target Prioritization through a Residue Agnostic Ligandability Assessment Platform

Identifying The Proteins To Which Small-Molecule Probes And Drugs Bind In Cells

Multiplexed Target Profiling with Integrated Chemical Genomics and Chemical Proteomics

Chemoproteomics and Chemical Probes for Target Discovery

Silyl Ether Enables High Coverage Chemoproteomic Interaction Site Mapping

Chemical Proteomics–Guided Discovery of Covalent Ligands for Cancer Proteins

Discovery of selective 2,4-diaminopyrimidine-based photoaffinity probes for glyoxalase i